Impact of Refractory Chronic Cough on Activities of Daily Living and Response to Acute High-intensity Exercise

August 21, 2026 updated by: Dr Oliver Price, University of Leeds

Chronic cough is a common and debilitating condition that affects up to 10% of the global population. The health impact of chronic cough is multifaceted and manifests both physical and psychological symptoms including syncope, chest pain, lethargy, depression and anxiety. It is now also recognised that chronic cough often leads to social isolation and may impact an individual's ability or confidence to undertake routine daily tasks / lead an active lifestyle.

The primary aim of this study is therefore to characterise the impact of refractory chronic cough on the ability to undertake daily activities - i.e., determine whether individuals with chronic cough exhibit impaired levels of physical activity during usual daily living when compared with healthy matched controls. A secondary aim is to assess the short-term impact of high-intensity exercise on cough (i.e., determine whether an acute bout of exercise alters cough frequency and/or severity).

Study Overview

Status

Terminated

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Yorkshire
      • Leeds, West Yorkshire, United Kingdom, LS2 9JT
        • University of Leeds

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Patients with refractory chronic cough will be recruited from the Hull Cough Clinic, Castle Hill Hospital.

Description

Inclusion Criteria:

  • Age >18 years
  • Chronic cough as per European Respiratory Society definition (>8 weeks duration)
  • High symptom burden (i.e., cough visual analogue scale >40 mm at pre-study screening)
  • Chest radiograph or CT within 3 years of the screening visit with no abnormalities considered to contribute to chronic cough

Exclusion Criteria:

  • Smokers or individuals who gave up smoking within 12 months
  • Smoking history >20 pack-years
  • Long-COVID or post-COVID syndrome (defined as symptoms lasting over 12-weeks in duration)
  • Recent exacerbation of cough within 4 weeks of inclusion
  • Respiratory tract infection within 4 weeks of inclusion
  • Currently taking any of the following medications:

    • ACE inhibitors and within 3 months of inclusion
    • Antitussives (opioids, pregabalin, gabapentin, amitriptyline, nortriptyline, or over the-counter medications) within 2 weeks of inclusion
    • Medical treatments for gastro-oesophageal reflux disease (GORD), eosinophilic bronchitis or other cough related conditions, initiated or changed (i.e., not in a stable regimen) for 4 weeks prior to inclusion
  • Medical history of asthma or exercise-induced bronchoconstriction (EIB), COPD, or chronic bronchitis in the judgement of the investigator
  • Medical conditions/history or other circumstances which, in the judgement of the investigators, could increase the risk of adverse events or bias the study results

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Refractory chronic cough (RCC)
Adults with refractory or unexplained chronic cough of ≥8 weeks' duration recruited from a specialist cough clinic.
Healthy controls
Adults without chronic respiratory disease recruited as a healthy comparison group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily step count
Time Frame: 1-week
Objectively measured using wrist-worn accelerometry over 7 days.
1-week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cough frequency
Time Frame: 24 h
Objectively measured using the Leicester Cough Monitor over 24 h
24 h
Post-exercise cough frequency
Time Frame: 24 h
Objectively measured using the Leicester Cough Monitor for 24 h following a standardised high-intensity exercise challenge
24 h

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

December 13, 2024

First Submitted That Met QC Criteria

January 3, 2025

First Posted (Actual)

January 9, 2025

Study Record Updates

Last Update Posted (Actual)

August 25, 2026

Last Update Submitted That Met QC Criteria

August 21, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe